for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oxford Immunotec Global PLC

OXFD.OQ

Latest Trade

14.12USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

12.15

 - 

19.10

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.12
Open
--
Volume
--
3M AVG Volume
4.59
Today's High
--
Today's Low
--
52 Week High
19.10
52 Week Low
12.15
Shares Out (MIL)
26.83
Market Cap (MIL)
381.00
Forward P/E
-88.75
Dividend (Yield %)
--

Latest Developments

More

Oxford Immunotec Reports Second Quarter 2019 Financial Results

Oxford Immunotec Reports Second Quarter 2019 Financial Results

Oxford Immunotec Appoints Patrick Balthrop Sr. As Chairman

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC,is a diagnostics company. It is focused on developing and commercializing tests for under-served immune-regulated conditions. Its product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Tick-borne disease is the collective name for diseases passed to humans through the bite of an infected tick. Its diagnostic tests for tick-borne infections include multiple laboratory developed tests (LDTs). Its tick-borne disease tests utilize molecular methods (such as polymerase chain reaction) and techniques to prosecute the immune system. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease.

Industry

Medical Equipment & Supplies

Contact Info

94C Innovation Drive

+44.1235.442780

http://www.oxfordimmunotec.com/north-america/company/about-us/

Executive Leadership

Richard A. Sandberg

Independent Chairman of the Board

Peter James Wrighton-Smith

Chief Executive Officer, Director

Matthew T E McLaughlin

Chief Financial Officer

Stefan C. Linn

Chief Operating Officer

Ronald A. Andrews

Independent Director

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-1.000

2017

-2.190

2018

0.590

2019(E)

-0.160
Price To Earnings (TTM)
15.91
Price To Sales (TTM)
5.79
Price To Book (MRQ)
1.75
Price To Cash Flow (TTM)
13.89
Total Debt To Equity (MRQ)
0.01
LT Debt To Equity (MRQ)
0.01
Return on Investment (TTM)
15.34
Return on Equity (TTM)
13.87

Latest News

BRIEF-Oxford Immunotec Reports Q1 Loss Per Share $0.40

* OXFORD IMMUNOTEC REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Oxford Immunotec Q4 Earnings Per Share $0.33

* OXFORD IMMUNOTEC REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-James Flynn Reports 5.1 Pct Passive Stake In Oxford Immunotec Global Plc As Of Jan 22

* JAMES FLYNN REPORTS 5.1 PERCENT PASSIVE STAKE IN OXFORD IMMUNOTEC GLOBAL PLC AS OF JANUARY 22 - SEC FILING Source text: [http://bit.ly/2BNPx1n] Further company coverage:

BRIEF-Oxford Immunotec Announces Preliminary Revenue For Q4

* FY2017 REVENUE VIEW $104.1 MILLION -- THOMSON REUTERS I/B/E/S

BRIEF-Oxford Immunotec And Qiagen Reached A Settlement In Lawsuit

* OXFORD IMMUNOTEC GLOBAL - CO, QIAGEN REACHED A SETTLEMENT IN LAWSUIT IN U.S. COURT ALLEGING PATENT INFRINGEMENT IN RELATION TO QIAGEN'S PRODUCTS

BRIEF-Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech AB​

* Oxford Immunotec Global Plc - on Nov 17, unit entered into a second amendment to purchase agreement with Mabtech AB

BRIEF-Oxford Immunotec Global Q3 loss per share $0.70

* Oxford Immunotec reports third quarter 2017 financial results

BRIEF-Oxford Immunotec announces update in patent infringement litigation

* Oxford Immunotec announces update in patent infringement litigation

BRIEF-Oxford Immunotec updates on amendment to supply agreement with StemCell Technologies ​

* Oxford Immunotec Global PLC - on Sept 1 unit entered into second amendment to supply agreement with StemCell Technologies Canada f/k/a StemCell Technologies

BRIEF-Oxford Immunotec appoints Stefan Linn as COO

* Oxford Immunotec appoints Stefan Linn as chief operating officer Source text for Eikon: Further company coverage:

BRIEF-Oxford Immunotec Global Plc announces pricing of underwritten public offering of ordinary shares

* Oxford Immunotec Global Plc announces pricing of underwritten public offering of ordinary shares

BRIEF-Oxford Immunotec Global announces agreement to sell 2.5 mln ordinary shares

* Oxford Immunotec Global Plc announces agreement to sell 2,500,000 ordinary shares

BRIEF-Oxford Immunotec Q2 loss per share $0.74

* Oxford immunotec reports second quarter 2017 financial results

BRIEF-Oxford Immunotec Global says unit entered into amendment to marketing authorization holder agreement with Riken Genesis

* Oxford Immunotec Global Plc - on july 24, unit of co entered into amendment to marketing authorization holder agreement with Riken Genesis Co., Ltd

BRIEF-Oxford Immunotec appoints Richard Wenstrup, MD, as chief medical officer

* Oxford Immunotec appoints Richard Wenstrup, MD, as chief medical officer Source text for Eikon: Further company coverage:

BRIEF-Oxford Immunotec announces favorable claim construction ruling in patent infringement litigation

* Oxford Immunotec announces favorable claim construction ruling in patent infringement litigation

BRIEF-Oxford Immunotec posts Q1 loss per share of $0.36

* Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

BRIEF-Oxford Immunotec reports Q3 loss per share $0.18

* FY2016 revenue view $83.7 million -- Thomson Reuters I/B/E/S

BRIEF-Oxford Immunotec acquires Immunetics

* Oxford Immunotec Global PLC - continue to expect to report full year 2016 revenue of between $82.5 and $84.5 million

BRIEF-Oxford Immunotec says entered credit, security and guaranty agreement

* On october 4, co entered into a credit, security and guaranty agreement and a credit, security and guaranty agreement

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up